Pilot Study Evaluating the efficacy and safety of Polymyxin B-immobilized Fiber Column (PMX) Hemoperfusion Treatment for Idiopathic Pulmonary Fibrosis with Acute Exacerbation

Pilot Study Evaluating the efficacy and safety of Polymyxin B-immobilized Fiber Column (PMX) Hemoperfusion Treatment for Idiopathic Pulmonary Fibrosis with Acute Exacerbation - Pilot Study Evaluating the efficacy and safety of Polymyxin B-immobilized Fiber Column (PMX) Hemoperfusion Treatment for Idiopathic Pulmonary Fibrosis with Acute Exacerbation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013116

Enrollment

Registered

2014-02-10

Start date

2014-02-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic pulmonary fibrosis

Interventions

Patients treated with Toraymyxin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) >= 20 and <=80 years of age 2) able and willing to provide informed consent. 3) meet all of the following inclusion criteria within one month; - increasing dyspnea - Frosted glass shadow, the permeation shadow which occurred in addition to a honeycomb lungs lesion with a chest image newly - decreasing PaO2 4) PF ratio <300 5) undergone PMX treatment before enrollment

Exclusion criteria

Exclusion criteria: 1) pregnant or lactating 2) history of hypersensitivity for blood purification or Extracorporeal circulation therapy 3) participated in another clinical research of non-approved medical device or drug , or has not passed the time of 5 times or more of the half-life in blood of a non-approved drug after the end of non-approved drug medication 4) difficulty in evaluation of this study; terminal cancer, chronic renal failure, the death within seven days are predicted 5) endotoxin blood symptom 6) respiratory infection, pneumothorax, pulmonary embolism, or heart failure 7) considered ineligible for the study by the investigator

Design outcomes

Primary

Measure	Time frame
- A survival rate after four weeks from the PMX treatment - Adverse Events occurred during follow-up period after PMX treatment	—

Secondary

Measure	Time frame
- Effect of PMX on P/F after one week from the PMX treatment - Effect of PMX on radiological image after one/four weeks from the PMX treatment - Effect of PMX on CRP in serum after one week from the PMX treatment - Effect of PMX on radiological image after four/twelve weeks from the PMX treatment - duration of mechanical ventilation - A survival rate after twelve weeks from the PMX treatment	—

Countries

Japan

Contacts

Public ContactHiroki Hayashi

Nippon Medical School Hospital Department of Pulmonary Medicine

s5075@nms.ac.jp03-3822-2131

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026